サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1747645

シンドロミック・マルチプレックス診断の世界市場

Syndromic Multiplex Diagnostics

出版日
ページ情報
英文 274 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
シンドロミック・マルチプレックス診断の世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

シンドロミック・マルチプレックス診断の世界市場は2030年までに38億米ドルに達する見込み

2024年に27億米ドルと推定されるシンドロミック・マルチプレックス診断の世界市場は、2024～2030年の分析期間においてCAGR 5.6%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである呼吸器疾患は、CAGR 4.4%を記録し、分析期間終了時には16億米ドルに達すると予測されます。消化器疾患セグメントの成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は7億3,640万米ドルと推定、中国はCAGR 8.7％で成長予測

米国のシンドロミック・マルチプレックス診断市場は、2024年に7億3,640万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.7%として、2030年までに7億4,820万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8％と5.5％と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の「シンドロミック・マルチプレックス診断」市場- 主要動向と促進要因のまとめ

マルチプレックスは迅速な疾患検出にどのような革命をもたらすか？

病原体が急速に進化し、ポイントオブケア検査への需要が高まる中、シンドロミック・マルチプレックス診断は臨床診断における変革の担い手として台頭してきました。従来の1検査1病原体モデルとは異なり、シンドロミック・パネルは呼吸器感染症、消化器疾患、中枢神経系疾患などの特定の臨床症候群の原因となる複数の病原体を同時に検出することができます。この技術は、迅速性と正確性が治療結果を左右する救急医療の現場で不可欠であることが証明されています。最近の進歩により、検査の所要時間は1時間以内に短縮され、タイムリーな臨床判断が容易になりました。COVID-19は、マルチプレックス検査の世界の認知度と普及を高める、かつてないきっかけとなりました。FDAやCEなどの規制機関はマルチプレックス診断パネルの承認を迅速に進め、臨床応用の拡大を促しています。

マルチプレックス診断は、小児医療や免疫不全の患者集団において特に重要です。単一の検査で重複感染を特定できるようになったことで、不必要な治療が激減し、抗菌薬耐性との闘いに役立っています。新興市場の企業は、小型化されたプラットフォームで革新を進め、装置の設置面積を縮小し、分散化された環境でのアクセシビリティを高めています。注目すべきは、AIを活用して解釈アルゴリズムを強化し、リアルタイムの意思決定サポートを提供する企業です。病院情報システムとのクラウドベースのデータ統合も大きなブレークスルーであり、縦断的な患者モニタリングと疫学的追跡を可能にしています。低資源ヘルスケアシステムからの需要が高まる中、遠隔地における診断ギャップを埋めるために、費用対効果の高いポータブルモデルが開発されています。

自動化とAIは検査能力のギャップを埋められるか？

シンドロミック・マルチプレックス診断における人工知能と自動化の役割は、かなりの勢いを増しています。先進的なプラットフォームは現在、ロボットによる分注、統合されたサーマルサイクラー、自動結果報告を組み込んでおり、人間の介入を大幅に減らし、エラー率を最小限に抑えています。AI駆動システムは、複雑なデータセットを解析し、あいまいな結果をより正確に解釈することで、病原体の同定を強化します。これらの開発によりスループットが大幅に向上し、伝染病流行時や大量の臨床検査室での大規模スクリーニングプログラムが実現可能になりました。機械学習はまた、アルゴリズムの精度を向上させるために、偽陽性率と偽陰性率を経時的に分析することによって、継続的なソフトウェアの最適化にも役立っています。

遠隔医療との統合はシンドロミック検査の有用性をさらに押し上げ、ヘルスケアプロバイダーが遠隔で検査を開始し、解釈することを可能にしています。特に、移動医療ユニットや、検査専門家が少ない地方の診断における使用事例を後押ししています。一方、シンドロミックシステムのスケーラビリティは、過酷な環境下での携帯性と効率性を重視する軍事組織や災害対応組織からも注目されています。新興企業やハイテク企業はこの分野に積極的に参入しており、しばしばバイオテクノロジー企業と提携して、診断と治療計画を統合したハイブリッドプラットフォームを共同開発しています。データのセキュリティと相互運用性は今やイノベーションの中心であり、共有エコシステムにおける検査結果の完全性を確保するためにブロックチェーンや分散型台帳が検討されています。

感染症以外の領域での導入の原動力は？

シンドロミック・マルチプレックス診断は伝統的に感染症に焦点を当ててきたが、最近の画期的な進歩により、腫瘍学、薬理ゲノミクス、自己免疫疾患など、感染症以外の領域にも利用が広がっています。現在、遺伝子マーカー、腫瘍変異、免疫応答指標を評価するためのマルチプレックスパネルが開発され、個別化医療における新たなフロンティアが開かれつつあります。マルチプレックスPCRや次世代シーケンシングパネルを用いたがんプロファイリングにより、臨床医は一度の検査で包括的な腫瘍生物学に基づいた治療を行うことができます。同様に、自己免疫パネルは、複数のバイオマーカーを同時に検出することにより、ループスや関節リウマチのような重複する症候群をより効果的に診断するのに役立ちます。

新生児集中治療室（NICU）では、マルチプレックス検査が先天性感染症や代謝異常の迅速な診断に役立っており、タイムリーな介入を可能にしています。薬理ゲノミクスの分野では、これらの検査は薬剤に対する患者固有の反応を評価するために使用され、投与量の最適化や副作用の軽減に役立っています。これは、ポリファーマシーが一般的な慢性疾患管理において特に適切です。また、シンドロミック診断とウェアラブル・ヘルス技術を組み合わせてプロアクティブ・モニタリング・システムを構築することへの関心も高まっており、慢性疾患の追跡や再発予測を再定義する可能性があります。製薬会社は診断ラボと協力して、患者を層別化し、より効果的に反応をモニターするために、臨床試験にマルチプレックス検査を組み込もうとしています。

シンドロミック・マルチプレックス診断市場の成長はいくつかの要因によってもたらされる...

シンドロミック・マルチプレックス診断市場の成長は、技術の進歩、ヘルスケアインフラの動向、臨床診療の進化に根ざしたいくつかの要因によって牽引されています。最も重要な要因は、病院と外来の両方で迅速かつ包括的な診断ソリューションに対する需要が高まっていることです。ヘルスケアシステムが効率を優先する中、マルチプレックス・プラットフォームが従来の培養検査や単一病原体検査に取って代わり、検査室の診断負担を軽減しています。マイクロ流体工学、ラボオンチッププラットフォーム、統合型バイオセンサーなどの技術革新により、診断システムの小型化が可能になり、地方や遠隔地での利用可能性が高まっています。感染症の急増は、抗生物質耐性の増加と相まって、ウイルスと細菌の病因を迅速に区別できる検査の必要性を高めています。

救急部、ICU、外来診療所からの最終需要も増加の一途をたどっており、特に呼吸器感染症、消化器感染症、性感染症に重点が置かれています。消費者の行動も進化しており、早期診断や予防的スクリーニングに対する一般市民の意識が高まっています。特に北米と欧州では、政府主導の検診プログラムと償還政策がこれをさらに後押ししています。小児および老年人口は、いずれも急速な疾患進行に脆弱であるため、採用を促進する主要な人口層です。さらに、新興市場における世界ヘルス構想では、人道的活動やパンデミック対策プログラムにおいてマルチプレックス診断薬が導入されています。最後に、大手診断薬メーカーによる戦略的投資や、公衆衛生機関と診断薬開発企業間の協力関係の高まりにより、製品パイプラインが加速しており、市場情勢は堅調かつ競争的です。

セグメント

タイプ（呼吸器系、消化器系、中枢神経系、その他のタイプ）、エンドユーザー（病院、診断研究所、その他のエンドユーザー）

調査対象企業の例（全34件）

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioFire Diagnostics（bioMerieux SA）
  • Bio-Rad Laboratories, Inc.
  • Cepheid（A subsidiary of Danaher）
  • Curetis（A subsidiary of OpGen, Inc.）
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35854

Global Syndromic Multiplex Diagnostics Market to Reach US$3.8 Billion by 2030

The global market for Syndromic Multiplex Diagnostics estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Respiratory Disease, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Gastrointestinal Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$736.4 Million While China is Forecast to Grow at 8.7% CAGR

The Syndromic Multiplex Diagnostics market in the U.S. is estimated at US$736.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$748.2 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global "Syndromic Multiplex Diagnostics" Market - Key Trends & Drivers Summarized

How Is Multiplexing Revolutionizing Rapid Disease Detection?

In an era of rapidly evolving pathogens and increasing demand for point-of-care testing, syndromic multiplex diagnostics has emerged as a transformative force in clinical diagnostics. Unlike traditional one-pathogen-per-test models, syndromic panels enable simultaneous detection of multiple pathogens responsible for a specific clinical syndrome, such as respiratory infections, gastrointestinal diseases, or central nervous system disorders. The technology has proven vital in emergency care settings where speed and accuracy can determine treatment outcomes. Recent advancements have reduced test turnaround times to under an hour, facilitating timely clinical decisions. COVID-19 served as an unprecedented catalyst, heightening global awareness and adoption of multiplex testing. Regulatory bodies like the FDA and CE have fast-tracked approvals for multiplex diagnostic panels, encouraging wider clinical application.

Multiplex diagnostics are particularly critical in pediatric care and immunocompromised patient populations, where co-infections are common and symptoms may be atypical. The ability to identify co-infections through a single test has drastically reduced the number of unnecessary treatments, helping combat antimicrobial resistance. Emerging market players are innovating with miniaturized platforms, reducing device footprint and increasing accessibility in decentralized settings. Notably, companies are leveraging AI to enhance interpretation algorithms and provide real-time decision support. Cloud-based data integration with hospital information systems is another major breakthrough, enabling longitudinal patient monitoring and epidemiological tracking. With growing demand from low-resource healthcare systems, cost-effective portable models are being developed to bridge diagnostic gaps in remote regions.

Can Automation and AI Bridge Laboratory Capacity Gaps?

The role of artificial intelligence and automation in syndromic multiplex diagnostics is gaining considerable momentum. Advanced platforms now incorporate robotic pipetting, integrated thermal cyclers, and automated result reporting, greatly reducing human intervention and minimizing error rates. AI-driven systems enhance pathogen identification by parsing through complex data sets to interpret ambiguous results more accurately. These developments have significantly expanded throughput, making large-scale screening programs feasible during epidemics or in high-volume clinical laboratories. Machine learning is also aiding in continuous software optimization by analyzing false-positive and false-negative rates over time to refine algorithm accuracy.

Telemedicine integration has further propelled the utility of syndromic testing, allowing healthcare providers to initiate and interpret tests remotely. In particular, this has boosted use cases in mobile health units and rural diagnostics where lab specialists are scarce. Meanwhile, the scalability of syndromic systems is attracting attention from military and disaster response organizations, who value portability and efficiency in austere environments. Start-ups and tech companies are entering the space aggressively, often partnering with biotech firms to co-develop hybrid platforms that integrate diagnostics with treatment planning. Data security and interoperability are now central to innovation, with blockchain and decentralized ledgers being explored to ensure test result integrity in shared ecosystems.

What’s Driving Adoption Beyond Infectious Diseases?

While syndromic multiplex diagnostics has traditionally focused on infectious diseases, recent breakthroughs are expanding its use into non-infectious realms such as oncology, pharmacogenomics, and autoimmune disorders. Multiplex panels are now being developed to assess genetic markers, tumor mutations, and immune response indicators, opening up new frontiers in personalized medicine. Cancer profiling using multiplex PCR or next-gen sequencing panels allows clinicians to tailor treatments based on comprehensive tumor biology in a single run. Similarly, autoimmune panels help diagnose overlapping syndromes like lupus and rheumatoid arthritis more effectively by detecting multiple biomarkers simultaneously.

In neonatal intensive care units (NICUs), multiplex testing is helping to rapidly diagnose congenital infections or metabolic disorders, ensuring timely interventions. In the pharmacogenomics sector, these tests are used to evaluate patient-specific responses to drugs, aiding in dose optimization and reducing adverse drug reactions. This is especially pertinent in chronic disease management where polypharmacy is common. There is also a growing interest in combining syndromic diagnostics with wearable health tech to create proactive monitoring systems, which could redefine chronic disease tracking and relapse prediction. Pharmaceutical companies are collaborating with diagnostic labs to integrate multiplex testing into clinical trials to stratify patients and monitor responses more effectively.

The Growth in the Syndromic Multiplex Diagnostics Market Is Driven by Several Factors…

The growth in the syndromic multiplex diagnostics market is driven by several factors rooted in technological advancements, healthcare infrastructure trends, and evolving clinical practices. The most significant driver is the increasing demand for rapid, comprehensive diagnostic solutions in both hospital and outpatient settings. As healthcare systems prioritize efficiency, multiplex platforms are replacing traditional culture and single-pathogen tests, reducing the diagnostic burden on laboratories. Innovations in microfluidics, lab-on-chip platforms, and integrated biosensors have enabled the miniaturization of diagnostic systems, increasing their availability in decentralized and rural locations. The proliferation of infectious diseases-coupled with rising antibiotic resistance-has intensified the need for tests that can distinguish between viral and bacterial etiologies swiftly.

End-use demand from emergency departments, ICUs, and ambulatory clinics continues to rise, with particular emphasis on respiratory, gastrointestinal, and sexually transmitted infections. Consumer behavior is also evolving, with increasing public awareness of early diagnosis and preventive screening. This is further supported by government-led screening programs and reimbursement policies, especially in North America and Europe. Pediatric and geriatric populations-both vulnerable to rapid disease progression-are key demographics driving adoption. Additionally, global health initiatives in emerging markets are deploying multiplex diagnostics in humanitarian and pandemic preparedness programs. Finally, strategic investments by major diagnostic players and rising collaborations between public health agencies and diagnostic developers are accelerating product pipelines, ensuring a robust and competitive market landscape.

SCOPE OF STUDY:

The report analyzes the Syndromic Multiplex Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Respiratory, Gastrointestinal, Central Nervous System, Other Types); End-Use (Hospitals, Diagnostics Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company (BD)
  • Biocartis
  • BioFire Diagnostics (bioMerieux SA)
  • Bio-Rad Laboratories, Inc.
  • Cepheid (A subsidiary of Danaher)
  • Curetis (A subsidiary of OpGen, Inc.)
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Syndromic Multiplex Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Integration of Syndromic Panels in Emergency Care Propels Market Growth
    • Rising Demand for Rapid, Point-of-Care Testing Accelerates Technology Adoption
    • Increased Incidence of Multi-Pathogen Infections Spurs Adoption of Multiplex Solutions
    • Growing Antimicrobial Resistance Strengthens Business Case for Syndromic Testing
    • Automation and Workflow Efficiency in Labs Drives Syndromic Diagnostic Uptake
    • Regulatory Push for Early Disease Detection Expands Market Opportunities
    • Miniaturization and Portability of Devices Drive Penetration in Remote Settings
    • Hospital Consolidation Trends Throw the Spotlight on Integrated Diagnostic Platforms
    • AI Integration in Diagnostic Decision Support Spurs Innovation in Test Panels
    • Expanding Applications in Veterinary and Food Safety Diagnostics Fuel Market Growth
    • Increased Reimbursement Support Across Developed Markets Drives Adoption
    • Rising Awareness Among Clinicians and Patients Accelerates Utilization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Syndromic Multiplex Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Gastrointestinal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Central Nervous System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION